Published in Proc Natl Acad Sci U S A on March 05, 2002
Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A (2003) 3.38
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Genetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selection. J Gen Virol (2005) 2.58
Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol (2010) 2.45
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
The West Nile virus mutant spectrum is host-dependant and a determinant of mortality in mice. Virology (2006) 1.72
Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev (2007) 1.65
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56
Role of the mutant spectrum in adaptation and replication of West Nile virus. J Gen Virol (2007) 1.46
Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One (2011) 1.39
Hepatitis C virus NS3 ATPases/helicases from different genotypes exhibit variations in enzymatic properties. J Virol (2003) 1.31
Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol (2005) 1.29
Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity. J Virol (2012) 1.25
Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol (2007) 1.21
The quasispecies nature and biological implications of the hepatitis C virus. Infect Genet Evol (2009) 1.14
Wide range of quasispecies diversity during primary hepatitis C virus infection. J Virol (2005) 1.10
HCV replication in PBMC and its influence on interferon therapy. World J Gastroenterol (2003) 1.08
Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol (2011) 1.01
Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus. Adv Virus Res (2010) 0.96
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol J (2008) 0.95
Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. Virol J (2007) 0.94
Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapy. Arch Virol (2010) 0.93
Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy. J Virol (2011) 0.92
Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One (2010) 0.90
Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection. J Virol (2009) 0.89
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med (2014) 0.89
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology (2008) 0.89
High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology (2009) 0.89
Topology of evolving, mutagenized viral populations: quasispecies expansion, compression, and operation of negative selection. BMC Evol Biol (2008) 0.88
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses (2010) 0.87
Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis (2010) 0.87
Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response. BMC Infect Dis (2010) 0.86
Experimental evolution of an RNA virus in wild birds: evidence for host-dependent impacts on population structure and competitive fitness. PLoS Pathog (2015) 0.86
Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection. Antivir Ther (2008) 0.86
Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. J Virol (2015) 0.85
Investigation of putative multisubtype hepatitis C virus infections in vivo by heteroduplex mobility analysis of core/envelope subgenomes. J Virol (2008) 0.84
Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J Clin Microbiol (2004) 0.84
Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing. J Virol (2014) 0.83
Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C. Eur J Pediatr (2004) 0.83
Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART). Hepatology (2007) 0.83
Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a. Virol J (2010) 0.82
Homogeneity of Powassan virus populations in naturally infected Ixodes scapularis. Virology (2010) 0.82
New take on comparative immunology: relevance to immunotherapy. Immunotherapy (2009) 0.82
Characterization of hepatitis C virus quasispecies by matrix-assisted laser desorption ionization-time of flight (mass spectrometry) mutation detection. J Clin Microbiol (2002) 0.81
Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. PLoS One (2008) 0.81
Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. J Virol (2013) 0.81
Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*. J Viral Hepat (2009) 0.81
Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua. J Virol (2014) 0.81
Influence of increased CD4 cell counts on the genetic variability of hepatitis C virus in patients co-infected with human immunodeficiency virus I. J Biomol Tech (2006) 0.80
Effect of oligonucleotide primers in determining viral variability within hosts. Virol J (2004) 0.80
Multigene tracking of quasispecies in viral persistence and clearance of hepatitis C virus. World J Gastroenterol (2005) 0.80
Seronegative hepatitis C virus infection in a child infected via mother-to-child transmission. J Clin Microbiol (2012) 0.79
Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome. BMC Infect Dis (2014) 0.79
Analysis of quasispecies in the viral 5' untranslated region of hepatitis C virus to evaluate ribavirin mutagenic effect in patients receiving ribavirin and interferon-alfa. Eur J Clin Microbiol Infect Dis (2004) 0.79
Evolution of the uniquely adaptable lentiviral envelope in a natural reservoir host. Retrovirology (2006) 0.79
Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. World J Gastroenterol (2014) 0.78
Monitoring of hepatitis C virus quasispecies in chronic infection by matrix-assisted laser desorption ionization-time of flight mass spectrometry mutation detection. J Clin Microbiol (2007) 0.77
Analysis of HCV quasispecies dynamic under selective pressure of combined therapy. BMC Infect Dis (2013) 0.77
Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin. PLoS One (2015) 0.77
Vertical transmission of hepatitis C virus: a tale of multiple outcomes. Infect Genet Evol (2013) 0.76
Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure. Dig Dis Sci (2007) 0.75
Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C. World J Gastroenterol (2008) 0.75
Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response. Hepat Mon (2013) 0.75
Occurrence of genetic modifications in core, 5'UTR and NS5b of HCV associated with viral response to treatment. Virol J (2014) 0.75
Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice. PLoS One (2016) 0.75
Expression of hepatitis C virus hypervariable region 1 and its clinical significance. World J Gastroenterol (2003) 0.75
Intrahost Selection Pressures Drive Rapid Dengue Virus Microevolution in Acute Human Infections. Cell Host Microbe (2017) 0.75
Vertical transmission of hepatitis C virus: variable transmission bottleneck and evidence of mid-gestation in utero infection. J Virol (2017) 0.75
Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol (1986) 36.06
Avoiding false positives with PCR. Nature (1989) 30.66
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science (1999) 6.21
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol (1992) 6.09
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis (2000) 6.05
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
Lack of protective immunity against reinfection with hepatitis C virus. Science (1992) 4.94
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med (1991) 4.79
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med (1996) 4.61
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A (1992) 4.47
At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci U S A (1993) 3.37
Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest (1995) 3.19
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology (2001) 2.39
Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol (1997) 2.11
Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology (1997) 1.90
Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis (2000) 1.75
Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology (1997) 1.72
Viral escape and the failure of cellular immune responses. Science (2000) 1.70
A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology (1996) 1.70
The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology (1992) 1.46
Interaction between the hepatitis C virus and the immune system. Semin Liver Dis (2000) 1.45
Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol (1997) 1.37
Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol (2000) 1.32
Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol (1999) 1.26
Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology (2000) 1.23
Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology (1995) 1.22
Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol (1997) 1.15
Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol (2000) 1.14
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology (1997) 1.10
Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology (2000) 1.10
Hepatitis C virus resistance to antiviral therapy. Hepatology (2000) 1.08
Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol (1996) 1.06
Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology (1994) 1.06
Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. J Med Virol (1999) 1.04
Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. Hepatology (2000) 1.03
Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology (1997) 1.01
Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol (1997) 1.00
Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology (1995) 1.00
Therapy of acute and chronic viral hepatitis. Adv Intern Med (1994) 0.99
Strategies and prospects for vaccination against the hepatitis C viruses. Curr Top Microbiol Immunol (2000) 0.92
Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance. Science (2000) 0.91
Hepatitis C virus and interferon resistance: it's more than just PKR. Hepatology (2001) 0.81
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
Retracted Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A (2010) 4.31
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Hepatitis E virus. Rev Med Virol (2003) 3.34
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A (2007) 2.69
Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis (2009) 2.62
Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology (2003) 2.45
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A (2005) 2.42
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A (2002) 2.02
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Hepatitis E. N Engl J Med (2012) 1.99
Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A (2010) 1.96
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A (2004) 1.96
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci U S A (2003) 1.93
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A (2008) 1.83
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A (2008) 1.82
Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci U S A (2011) 1.81
Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis (2008) 1.75
Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A (2009) 1.72
The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol (2009) 1.71
Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 1.66
In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. J Virol (2004) 1.66
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol (2007) 1.61
Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components. Transfusion (2011) 1.59
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol (2010) 1.55
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology (2008) 1.55
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 1.53
The open reading frame 3 gene of hepatitis E virus contains a cis-reactive element and encodes a protein required for infection of macaques. J Virol (2005) 1.50
Running like water--the omnipresence of hepatitis E. N Engl J Med (2004) 1.49
ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro. J Virol (2006) 1.47
Cigarette smoking and appendectomy: effect on clinical course of diverticulosis. Dig Liver Dis (2010) 1.43
High prevalence of hepatitis E antibodies in pregnant Egyptian women. Trans R Soc Trop Med Hyg (2005) 1.40
HCV natural history: the retrospective and prospective in perspective. J Hepatol (2005) 1.40
Thermal stability of hepatitis E virus. J Infect Dis (2005) 1.39
Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology (2003) 1.39
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology (2005) 1.38
An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. Transfusion (2013) 1.36
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 1.35
Hidden danger: the raw facts about hepatitis E virus. J Infect Dis (2010) 1.35
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol (2008) 1.33
Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif. J Virol (2010) 1.32
Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology (2006) 1.31
Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A (2005) 1.29
Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay. J Gen Virol (2006) 1.29
Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period. J Virol (2011) 1.28
B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc Natl Acad Sci U S A (2010) 1.26
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol (2008) 1.26
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A (2003) 1.26
Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J Virol (2004) 1.25
Apolipoprotein c1 association with hepatitis C virus. J Virol (2008) 1.24
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A (2007) 1.24
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology (2011) 1.23
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis (2010) 1.21
Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion (2003) 1.19
Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis (2003) 1.18
Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med (2012) 1.18
Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies. Virol J (2009) 1.17
Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles. J Virol (2007) 1.16
Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci U S A (2012) 1.15
Detection of anthrax toxin by an ultrasensitive immunoassay using europium nanoparticles. Clin Vaccine Immunol (2009) 1.15
An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine (2004) 1.15
Epidemic of hepatitis E in a military unit in Abbotrabad, Pakistan. Am J Trop Med Hyg (2002) 1.15
High prevalence of hepatitis E antibodies among Danish prisoners and drug users. J Med Virol (2002) 1.14
Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc Natl Acad Sci U S A (2009) 1.14
Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities. Trans R Soc Trop Med Hyg (2005) 1.12
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci U S A (2006) 1.11
Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis (2011) 1.10
In vitro and in vivo mutational analysis of the 3'-terminal regions of hepatitis e virus genomes and replicons. J Virol (2005) 1.09
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemiol Ment Health (2007) 1.08
Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci U S A (2009) 1.08
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc Natl Acad Sci U S A (2012) 1.07
Spatial configuration of hepatitis E virus antigenic domain. J Virol (2010) 1.05
Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin Infect Dis (2006) 1.04